Inspire Medical Systems Inc
$ 57.59
2.02%
17 Apr - close price
- Market Cap 1,658,437,000 USD
- Current Price $ 57.59
- High / Low $ 58.23 / 56.37
- Stock P/E 11.54
- Book Value 27.33
- EPS 4.99
- Next Earning Report 2026-05-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.20 %
- 52 Week High 163.35
- 52 Week Low 48.30
About
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and Europe. The company is headquartered in Golden Valley, Minnesota.
Analyst Target Price
$74.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-11 | 2025-11-03 | 2025-08-04 | 2025-05-05 | 2025-02-10 | 2024-11-04 | 2024-08-06 | 2024-05-07 | 2024-02-06 | 2023-11-07 | 2023-08-01 | 2023-05-02 |
| Reported EPS | 1.65 | 0.38 | 0.45 | 0.1 | 1.15 | 0.6 | 0.32 | -0.34 | 0.49 | -0.29 | -0.41 | -0.53 |
| Estimated EPS | 0.6789 | -0.19 | 0.2 | -0.23 | 0.72 | 0.06 | -0.14 | -0.65 | -0.09 | -0.58 | -0.57 | -0.66 |
| Surprise | 0.9711 | 0.57 | 0.25 | 0.33 | 0.43 | 0.54 | 0.46 | 0.31 | 0.58 | 0.29 | 0.16 | 0.13 |
| Surprise Percentage | 143.0402% | 300% | 125% | 143.4783% | 59.7222% | 900% | 328.5714% | 47.6923% | 644.4444% | 50% | 28.0702% | 19.697% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.36 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: INSP
2026-04-17 06:40:31
Inspire Medical Systems director Ellis Gary Lee was granted 518 shares of common stock as a stock award, valued at $52.07 per share. These shares were received in lieu of cash fees, following the company’s Non-Employee Director Compensation Policy. After this transaction, Lee directly holds 7,276 shares of Inspire Medical Systems common stock.
2026-04-16 20:09:22
Inspire Medical Systems director Georgia Melenikiotou received a grant of 307 shares of common stock, valued at $52.07 per share, in lieu of cash fees. This transaction brings her total direct holdings to 4,473 shares. This grant was issued under the company's Non-Employee Director Compensation Policy, as detailed in a Form 4 SEC filing.
2026-04-16 20:09:21
Shelley G. Broader, a director at Inspire Medical Systems (INSP), received a grant of 342 shares of common stock valued at $52.07 per share. This grant was provided in lieu of cash fees, aligning with the company's Non-Employee Director Compensation Policy. Following this transaction, Broader directly holds 4,909 shares of Inspire Medical Systems Common Stock.
2026-04-16 12:40:13
A product liability lawsuit has been filed against Inspire Medical Systems Inc., alleging that an Inspire sleep apnea implant malfunctioned and delivered prolonged electrical shocks to a Louisiana man. The complaint claims the device was defectively designed and inadequately tested, leading to severe injuries, surgical removal, and ongoing harm. Inspire also faces investor class action lawsuits over alleged misrepresentation of device safety and performance.
2026-04-15 17:40:14
Truist Financial has lowered its price target for Inspire Medical Systems (NYSE:INSP) from $70.00 to $64.00, maintaining a "hold" rating, implying a potential 10.08% upside from the stock's previous close. The company recently surpassed quarterly earnings and revenue estimates, with revenue increasing 12.2% year-over-year. Despite the revised price target, the consensus among analysts remains a "Hold" with a wide range of price targets, averaging $101.41.
2026-04-15 05:39:41
This article provides the Q2 2025 earnings call transcript for Inspire Medical Systems, Inc. (NYSE:INSP). It covers the company's financial performance, operational updates, and outlook as discussed by management during the call.
